SIU 2021 Abstract Submission Guidelines

Last Updated: October 18, 2021

Abstracts which do not abide by the submission guidelines will not be sent for review and/or will not be eligible for presentation at SIU 2021. Please review the guidelines below.

1. Basic Information

i. Important Dates

*All deadlines (with the exception of the ePoster Upload Deadlines) are 11:59 PM Eastern Daylight Time (EDT) and are subject to change.

ii. Learning Objectives

The 2021 Congress Learning Objectives can be consulted on the SIU Scientific Programme webpage.

2. Rules for Authors

i. Prior Publication of Material

The SIU Congress is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before November 10, 2021. If the work has been presented at another meeting, the author must disclose when and where it was presented on the submission form, so that the Abstract Review Committee can make its decision based on all available details.

ii. Objectivity

The SIU is committed to offering participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the SIU urges all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.

iii. Registration

Presenting Authors must register before July 30, 2021. Abstract presenters who are not SIU members are encouraged to join, as this means a possible savings of at least €200 on registration fees. All expenses such as registration, visa, airfare, lodging, etc. associated with the presentation of accepted abstracts are the responsibility of the presenter. Additional information concerning visas can be consulted on the UAE Visa Information webpage. Presenting Authors unable to travel/attend in-person must register for virtual attendance.

iv. Failure to Present

Inability to attend in-person will not result in withdrawal of your abstract(s) for SIU 2021.

v. Abstract Revisions

Abstracts may not be revised or resubmitted after the deadline of May 30, 2021.

vi. Abstract Withdrawal

Please submit abstract withdrawal requests in writing via email to scientific.programme@siu-urology.org by July 30 2021 with your submission ID number(s).

vii. Change of Presenting Author

Please submit requests in writing via email to scientific.programme@siu-urology.org by July 30, 2021 with your submission ID number(s). After this date, changes may not be reflected online and on any printed materials.

3. Rules for Presentation

i. Abstract Acceptance

Each abstract will be blinded and scored by up to three reviewers. Abstracts will be accepted on the basis of scientific merit. The Scientific Committee reserves the right to assign final presentation categories and alter topics/subtopics in the best interest of the programme.

ii. Publication and Copyright

All accepted abstracts will be published on SIU Academy as an ePoster with voice-over as well as a supplement of SIUJ. Publications of abstracts on SIU Academy and SIUJ implies transfer of copyright of the article to the Publisher. This will ensure the widest possible protection and dissemination of information under copyright laws.

By submitting an abstract, the submitter (and its co-authors) agree to the conditions specified in the guidelines.

iii. Presentation Types

All accepted abstracts will be published on SIU Academy, the SIU’s online e-Learning platform, as an ePoster with a 3 minute voice-over as well as a supplement of SIUJ. Submitters will be contacted with additional information on ePoster and voice-over recording instructions.

Presentation categories are as follows:

4. Preparation of Abstracts

i. Language

Abstracts must be written and presented in English. Careful typing and proofreading are essential. If accepted, the abstract will be published as submitted. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English will be glaringly apparent in the published abstract. Once the abstract is submitted, changes, corrections or rewording will not be possible. Presenters are requested to devote the necessary attention to language in order to avoid deviations from the use of good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision.

ii. Word Count

Abstracts must not exceed 350 words. Deduct 50 words for each table, graphs or figures included (to a maximum of 1 page on US Letter, 8.5 x 11-inch paper). For example, with 2 figures, the maximum word count is 250.

iii. Images, Tables and Graphs

Images are not permitted as they do not reproduce well. Brief and clear tables, graphs and figures are accepted (maximum of 1 page on US Letter, 8.5 x 11-inch paper).

iv. Topic Area

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate topic as indicated on the submission form.

v. Learning Objectives

3-4 Educational Objectives must be submitted for each abstract. For more information, consult: Writing Clear Learning Objectives.

vi. Abstract Title

Your abstract must have a short, specific title (no abbreviations) that indicates the nature of the investigation. Please use title case. Example: "Complications in Laparoscopic Transperitoneal Partial Nephrectomy." Consult the Sample Abstract at the bottom of this page for additional information.

vii. Sections

Abstracts must include the following four distinct sections:

• Introduction and Objectives
• Materials and Methods
• Results
• Conclusion

viii. Drug Names

Use generic drug names.

ix. Abbreviations

Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase.

x. Acknowledgments

Do not include references, credits or grant support.

xi. Author Names and Affiliations

Author names and affiliations should not be present in the abstract title and abstract content as the abstract must be blinded for review.

List of Authors: Do not include the authors list directly with your abstract. Only submit this information on the online form. There is only one presenting author permitted per submission. All Presenting Authors must complete, sign and submit a Conflict of interest disclosure form.

Spelling: If an author's name appears on more than one abstract, it must be identical on each abstract in order to ensure proper indexing.

xii. Human Experimentation

Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the investigation should have been conducted in accordance with the principles of the World Medical Association’s Helsinki Declaration. The Scientific Committee may inquire further into ethical aspects when evaluating the abstract(s).

xiii. Abstract Data

Abstracts that describe single clinical cases, or investigations of compounds that involve inadequate numbers of study subjects, or abstracts that lack quantitative data will not be accepted. Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced. Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified. Statements such as "results will be discussed" will automatically disqualify the abstract. Reviewers may require specific data on which to base their evaluation.

Bear in mind that your abstract will be rated according to the following criteria:

• Is the design of the study valid?
• Are the methods appropriate?
• What is the significance of the results?
• Is the event described in the case report significant

5. Other Submissions

i. Video Submissions

If you wish to submit a video, please use the following link to upload your file: http://video.siu-urology.org/. Please note that videos must be uploaded prior to the submission deadline in order to be considered for review, and also note that a video submission must include an abstract.

All videos must be in the final format and include the exact title in the submission title. If copyrighted music is included in the video production, the submitter must first receive permission from the copyright owner(s) to use the music for educational purposes.

The video must be blinded for review; in other words no author names, patient names, affiliations, and faces should be visible. Maximum duration of video is 7 minutes. The video must include English commentary.

ii. Late-Breaking Abstracts

The Late-Breaking Abstract submission is solely for abstracts with late-breaking data and not for abstracts submitted “late”, after the submission deadline. In order to fulfil the criteria for a late-breaking abstract you must enter the reasons why your abstract is a late-breaking abstract. Failure to do so, will mean that the abstract will not be reviewed.

Please ensure that the abstract:

• Meets the criteria stipulated under Section 4 of the Guidelines (i.e the abstract has four distinct sections: Introduction, Materials and Methods, Results and Conclusion and has no more than 350 words).
• Includes a disclosure form signed by the Presenting Author. (Additional information can be found under 6 (ii)).

Please submit your abstract by sending an email to scientific.programme@siu-urology.org with the subject line “Late-Breaking Abstract” by September 24, 2021.

Accepted late-breaking abstracts will be presented in a plenary session at SIU 2021 and as an ePoster on SIU Academy.

iii. SANTU Submissions

Please note that the abstracts that will be considered for SANTU will be only the ones describing surgical techniques, medical management or devices that will be affordable in low-income countries. Abstracts submitted to SANTU that do not comply to the "affordability rule" will not be considered. Only authors of submissions selected for SANTU will be contacted by SANTU Organizers. Please note that while the same abstract may be submitted for both SIU and SANTU, its status with one does not impact the other. SANTU abstracts are not published in SIU Journal (SIUJ), but will be included as ePosters on SIU Academy.

6. References

i. Sample Abstract

Complications in Laparoscopic Transperitoneal Partial Nephrectomy

Introduction and Objectives: We review the complications of laparoscopic partial
nephrectomy in a single surgeon series.

Materials and Methods: Between July 1999 and April 2006, a total of 125 patients underwent laparoscopic transperitoneal partial nephrectomy. Mean patient age was 58 years (range 33 to 87) and male to female ratio was 2:1. In 43 patients (34%) the procedure was hand-assisted. A database was kept prospectively for all patients.

Results: Mean operative time was 104 minutes (range 35 to 180) and average surgical bleeding was 258 mL (range 0 to 2000). For procedures with warm ischemia, mean arterial clamping time was 26 minutes (range 15 to 60). Mean tumor size was 2.7 cm (range 1 to 7). A total of 14 patients (11.2%) had one or more complications which were intraoperative 6 (4.8%) and postoperative 8 (6.4%) with two delayed complications. Intraoperative hemorrhage occurred in 6 cases (4.8%), and postoperatively in another 6 (4.8%). Intraoperative hemorrhage was managed in 2 cases with laparoscopic radical nephrectomy and in 4 cases with intracorporeal suture. Postoperative hemorrhage required reoperation in 4 patients: two open radical nephrectomies, one laparoscopic radical nephrectomy and one laparoscopic re-suture of the kidney. The remaining two patients were managed with endovascular (percutaneous) embolization. Urine leakage occurred in one case (0.8%) and was managed conservatively with a double-J stent. A digestive hemorrhage and a pulmonary embolism were presented by two patients (1.6%). Transfusion rate was 10.4%. No case required conversion to open surgery. Mean hospital stay was 3.6 days (range 1 to 12).

Conclusion: Laparoscopic transperitoneal partial nephrectomy is technically demanding with a high potential for complications. The most frequent complication is either intra- or post-operative hemorrhage. For delayed bleeding, endovascular techniques are safe and effective and thus our first choice in the stable patient.

ii. Sample Signed COI

The Conflict of Interest disclosure form can be accessed here. Please consult the Sample Signed COI webpage. If you encounter any issues filling out the form, please write to scientific.programme@siu-urology.org with your computer type (Windows, Macintosh, Linux) and available pdf reading software (Adobe Acrobat Pro, Preview) or print out the form and fill it out by hand.